As many of you may know, the National Institutes of Health (NIH) plans to end funding to the Pharmacogenomics Research Network once the current grants expire in 2020. Accordingly, the PGRN is looking to the future of pharmacogenomics research and implementation by partnering with other organizations and potentially forming a new global pharmacogenomics consortium.
We would like to get feedback on how a new PGx consortium would best serve the community, so please complete the survey link below (and forward to any other PGx researchers you may know) by February 9, 2018.
Survey Link: https://ucsf.co1.qualtrics.com/jfe/form/SV_a44wfkmSYHvrKWp
We are excited to be conducting a national search for a new position as Director of Phamacogenomics and Henry Rutgers Professor of Phamacogenomics, a senior faculty position at Rutgers Biomedical & Health Sciences (RBHS) of Rutgers, The State University of New Jersey.
Please read the recruitment letter for details and to apply:
The All of Us Research Program aims to build one of the largest, most diverse datasets of its kind for health research, with one million or more volunteers nationwide, who will sign up to share their information over time. Researchers will be able to access participants’ de-identified information for a variety of studies to learn more about the biological, behavioral, and environmental factors that influence health and disease. Their findings may lead to more individualized health care approaches in the future.
All of Us is collecting ideas through something called a “use case” that describes a health problem or research question of interest. These ideas will be considered at a Research Priorities Workshop in March 2018 and help the program identify new features to add to support research across a range of health topics.
You may provide input through February 9, 2018, at https://allofusresearchpriorities.ideascale.com/.
The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database published in Clinical Pharmacology & Therapeutics
The Human Cytochrome P450 (CYP) Allele Nomenclature Database, a critical resource for the pharmacogenetics and genomics communities, has transitioned to the Pharmacogene Variation (PharmVar) Consortium. In this update we provide a summary of the current database, provide an overview of the PharmVar consortium, and highlight the PharmVar database which will serve as the new home for pharmacogene nomenclature.
The PGRN Best Trainee Abstract Awards were presented on October 19, 2017 at the Pharmacogenomics Poster Session at the ASHG 2017 Annual Meeting to the following individuals:
We congratulate these winners and all participants for their excellent presentations of cutting-edge pharmacogenomics research.
The American Physiological Society Journal ‘Physiological Genomics’ is has released a new article format developed exclusively for small-scale SNP data to be rapidly peer-reviewed, called PG SNPs. Associations reported may be as few as a single SNP validation study for any complex polygenic trait. Manuscripts submitted under this peer-reviewed Call for Papers are limited to 2 pages and are required to be presented in the template format designed exclusively for PG SNPs. To facilitate the submission process of such manuscripts with a small but definitive dataset, authors will have access to an easy-to-use, pre-existing template to generate the manuscript. For links to the manuscript submission file formats developed specifically for the PG SNPs article type and other details, please visit
PGRN Pharmacogenomics iPSC Library and Service (PiLS), is seeking applications for pilot projects, to utilize gene edited iPSC clones for SNP validation studies for pharmacogenomics research. Three projects will be selected for service at minimal cost to the investigators.
Eligibility: Any current PGRN member in an academic institute can submit a proposal
Application process: Applicants should write a 5 page proposal (A-F).
The deadline for the complete application is December 31, 2017.
Letters of intent are encouraged, to be submitted by November 30, 2017.
Letters of intent and final applications should be sent electronically (as a single pdf file) to Katherine Santostefano, PhD (firstname.lastname@example.org)
The selected applicants are expected to submit progress reports one year after receiving the cell lines.
PharmVar will serve as a central repository for pharmacogene variation to facilitate allele (haplotype) designation and the interpretation of pharmacogenetic test results to guide precision medicine.
PharmVar is a PGRN resource funded by NIGMS.
After September 26, 2017, please visit PharmVar.org to access content of the original P450 Nomenclature Database
We had a good turn out at the last PGRN-Wide Member Call on September 8th. Below are some key highlights from the call:
The Hub team